A Single-Arm, Open-Label, Phase I Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients With Severe, Refractory Systemic Lupus Erythematosus
Latest Information Update: 16 May 2025
At a glance
- Drugs Obecabtagene autoleucel (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms CARLYSE
- Sponsors Autolus
Most Recent Events
- 08 May 2025 Planned End Date changed from 1 Oct 2025 to 1 Dec 2026.
- 08 May 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Dec 2025.
- 01 Apr 2024 New trial record